TherapeuticsMD, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
TherapeuticsMD, Inc. (TXMD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $217.57 per share for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2024-08-12
- TherapeuticsMD, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $219.07, a 24.63% increase year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $175.77.
- TherapeuticsMD, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $206.15, a 9.01% decline from fiscal 2022.
- TherapeuticsMD, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $226.56, a 12.72% increase from fiscal 2021.
- TherapeuticsMD, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $201.00, a 5245.74% increase from fiscal 2020.
- TherapeuticsMD, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2020 was $3.76, a 32.50% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $217.57 10-Q · filed 2024-08-12 | ||||
| 2023-12-31 | $206.15 10-K · filed 2024-03-29 | ||||
| 2023-09-30 | $206.54 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $203.84 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $219.07 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $226.56 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $238.45 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $243.77 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | $175.77 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $201.00 10-K · filed 2023-04-07 | $4.02 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $5.59 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $5.90 10-Q · filed 2021-08-04 | ||||
| 2020-12-31 | $3.76 10-K · filed 2022-03-23 | ||||
| 2019-12-31 | $5.57 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |